Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: A meta-analysis

Cancer Investigation

Volumn 29, Issue 1, 2011, Pages 78-85

  Zou, Yan Feng ^a   Yuan, Feng Lai ^a,b   Feng, Xiao Liang ^a   Tao, Jin Hui ^a   Ding, Ning ^a   Pan, Fa Ming ^a   Wang, Fang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Carcinogenesis; Genetic polymorphisms; Meta analysis; NFKB1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; NF-KAPPA B P50 SUBUNIT; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 78650447464     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.535054     Document Type: Article

References (56)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?Lancet 2001;357:539-545.
2. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 inimmune cell biology. Biochem J 2004;382:393-409.
3. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relationto susceptibility of tumour and other diseases. Histol Histopathol2007;22:1387- 1398.
4. Sen R, Baltimore D. Inducibility of kappa immunoglobulinenhancer-binding protein NF-kappa B by a posttranslationalmechanism. Cell 1986;47:921-928.
5. Chen F, Castranova V, Shi X, Demers LM. New insights into therole of nuclear factor-kappaB, a ubiquitous transcription factor inthe initiation of diseases. Clin Chem 1999;45:7-17.
6. Le Beau MM, Ito C, Cogswell P, Espinosa R, 3rd.; Fernald AA,Baldwin AS Jr. Chromosomal localization of the genes encodingthe p50/p105 subunits of NF-kappa B (NFKB2) and the I kappaB/MAD-3 (NFKBI) inhibitor of NF-kappa B to 4q24 and 14q13,respectively. Genomics 1992;14:529-531.
7. Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomallocalization of genes encoding the transcription factors, c-rel,NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence insitu hybridization. Oncogene 1993;8:191-193.
8. Héron E, Deloukas P, van Loon AP.The complete exon-intronstructure of the 156-kb human gene NFKB1, which encodes thep105 and p50 proteins of transcription factors NF-kappa B andI kappa B-gamma: implications for NF-kappa B-mediated signaltransduction. Genomics 1995;30:493-505.
9. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ,Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, GregersenPK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM,Nouvet FJ, Brant SR. Functional annotation of a novel NFKB1promoter polymorphism that increases risk for ulcerative colitis.Hum Mol Genet 2004;13:35-45.
10. Zhang P,Wei Q, Li X,Wang K, Zeng H, Bu H, Li H. A functionalinsertion/ deletion polymorphism in the promoter region of theNFKB1 gene increases susceptibility for prostate cancer. CancerGenet Cytogenet 2009;191:73-77.
11. Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism ofNFKB1 promotermay correlate to the susceptibility of gastric cancerin aged patients. Surgery 2009;145:280-285.
12. Tang T, Cui S, Deng X, Gong Z, Jiang G, Wang P, Liao B, Fei Z,Xian S, Zeng D, Li J. Insertion/deletion polymorphism in the promoterregion of NFKB1 gene increases susceptibility for superficialbladder cancer in Chinese. DNA Cell Biol 2009;28:1-4.
13. Burnik FS, Yalcin S. NFKB1 -94 insertion/deletion ATTG polymorphismin gastroenteropancreatic neuroendocrine tumors.Chemotherapy 2009;55:381-385.
14. Lehnerdt GF, Bankfalvi A, Grehl S, Adamzik M, Lang S, SchmidKW, Siffert W, Riemann K. No association of the NF-kappaB1-94ins/delATTG promoter polymorphism with relapse-free andoverall survival in patients with squamous cell carcinomas ofthe head and neck region. Int J Immunopathol Pharmacol2008;21:827-832.
15. Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, SiffertW. Insertion/deletion polymorphism in the promoter of NFKB1ficialbladder cancer. Int J Clin PharmacolTher 2007;45:423-430.
16. RiemannK, Becker L, StruweH, Nückel H, Dührsen U, Alakus H,Winde G, Neuhäuser M, Rübben H, Schmitz KJ, WohlschlaegerJ, Schmid KW, Siffert W. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectaland renal cell carcinoma as well as disease progression inB-cell chronic lymphocytic leukemia. Pharmacogenet Genomics2006;16:783-788.
17. Zhou B, Rao L, Li Y, Gao L,Wang Y, Chen Y, XueH, Song Y, PengY, Liao M, Zhang L. A functional insertion/deletion polymorphismin the promoter region of NFKB1 gene increases susceptibilityfor nasopharyngeal carcinoma. Cancer Lett 2009;275:72-76.
18. Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G,Carstensen J, Zhang ZY, Sun XF. Swedish Low-Risk ColorectalCancer Study Group. Polymorphism in the promoter region ofthe NFKB1 gene increases the risk of sporadic colorectal cancerin Swedish but not in Chinese populations. Scand J Gastroenterol2007;42: 1332-1338.
19. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphismsin NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk,clinicopathological features and tumor progression in Swedishmelanoma patients. J Cancer Res Clin Oncol 2007;133:859-866.
20. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functionalpolymorphism in NFKB1 promoter is related to the risksof oral squamous cell carcinoma occurring on older male areca(betel) chewers. Cancer Lett 2007;243:47-54.
21. Egger M, Davey Smith G., Schneider M, Minder C. Bias inmeta-analysis detected by a simple, graphical test. Br Med J1997;315:629-634.
22. CochranWG. The combination of estimates fromdifferent experiments.Biometrics 1954;10:101-129.
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis.Stat Med 2002;21:1539-1558.
24. Mantel N, Haenszel W. Statistical aspects of the analysis ofdta from retrospective studies of disease. J Natl Cancer Inst1959;22:719-748.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. ControlClin Trials 1986;7:177-188.
26. Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Kang BW, KimGC, Lee MH, Jeon SW, Chung HY, Yu W. No association of theNFKB1 insertion/deletion promoter polymorphism with survivalin patients with gastric cancer. Jpn J Clin Oncol 2009;39:497-501.
27. Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM,Ruder AM, Linet MS, Yeager M, Wang Z, Orr N, Fine HA, KwonD,ThomasG, RothmanN, InskipPD, Chanock SJ. Common variationin genes related to innate immunity and risk of adult glioma.Cancer Epidemiol Biomarkers Prev 2009;18:1651-1658.
28. Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P,Ambinder RF, Zheng T, Mueller NE. Polymorphic variation inNFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev 2009;18:976-986.
29. Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, AndersenNF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, GregersenH, Vogel U.The polymorphism IL-1beta T-31C is associated witha longer overall survival in patients with multiple myeloma undergoingauto-SCT. Bone Marrow Transplant 2009;43:539-545.
30. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, CunninghamJM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG,Habermann TM, Ansell SM, Slager SL. Genetic variation in tumornecrosis factor andthe nuclear factor- kappaBcanonicalpathwayand risk of non-Hodgkin's lymphoma. Cancer EpidemiolBiomarkers Prev 2008;17:3161-3169.
31. Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ,Gonsky R, Cong Y, Vasiliauskas EA, Ippoliti A, Elson CO, RotterJI, Targan SR. Linkage of Crohn's disease-related serologicalphenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation. Gut2009;58:60-67.
32. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, VanBovenDJ, Paré L, CulverhouseR,McLeodHL, BaigetM. Irinotecanpharmacogenetics: influence of pharmacodynamic genes.Clin Cancer Res 2008;14:1788-1796.
33. Domenyuk VP, Litovkin KV, Verbitskaya TG, Dubinina VG,Bubnov VV. Identification of new DNA markers of endometrialcancer in patients from the Ukrainian population. Exp Oncol2007;29:152-155.
34. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M,de Oca J, Capella G, Canzian F, Bellvitge Colorectal CancerStudy Group. Association of common polymorphisms in inflammatorygenes interleukin (IL)6, IL8, tumor necrosis factoralpha, NFKB1, and peroxisome proliferator-activated receptorgamma with colorectal cancer. Cancer Res 2003;63:3560-3566.
35. Curran JE, Weinstein SR, Griffiths LR. Polymorphic variantsof NFKB1 and its inhibitory protein NFKBIA, and their involvementin sporadic breast cancer. Cancer Lett 2002;188:103-107.
36. ParkinDM, Bray F, Ferlay J, Pisani P. Estimating theworld cancerburden: Globocan 2000. Int J Cancer 2001;94:153-156.
37. Kuper H, AdamiHO, Trichopoulos D. Infections as a major preventablecause of human cancer. J Intern Med 2000;248:171-183.
38. Karin M. Nuclear factor-kappaB in cancer development and progression.Nature 2006;441:431-436.
39. Karin M, Greten FR. NF-kB: linking inflammation and immunitycancer development and progression. Nat Rev Immunol2005;5:749-759.
40. Karin M. NF-kB and cancer: mechanisms and targets. Mol Carcinog2006;45:355-361.
41. Luo JL, Kamata H, Karin M. IKK/NF-kB signaling: balancinglife and death-a new approach to cancer therapy. J Clin Invest2005;115:2625-2632.
42. Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R, Williams CL. Smg-GDS regulates cell proliferation,migration, and NF-kappa B ranscriptionalactivity in non-small cell lung carcinoma. J Biol Chem2008;283:963-976.
43. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S,Nakshatri H. NF-kappaBrepresses E-cadherin expression and enhancesepithelial to mesenchymal transition of mammary epithelialcells: potential involvement of ZEB-1 and ZEB-2. Oncogene2007;26:711-724.
44. Yang J, Pan WH, Clawson GA, Richmond A. Systemic targetinginhibitor of kappaB kinase inhibitsmelanoma tumor growth.CancerRes 2007;67:3127-3134.
45. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F,Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, BiscottiT, Labianca R, Falcone A, Cascinu S. Nuclear factor-kB tumor expressionpredicts response and survival in irinotecan-refractorymetastatic colorectal cancer treated with cetuximab-irinotecantherapy. J Clin Oncol 2007;25:3930-3935.
46. AnnunziaaCM, Davis RE, DemchenkoY, BellamyW, Gabrea A,Zhan F, Lenz G,Hanamura I,Wright G, Xiao W,Dave S,Hurt EM,Tan B, ZhaoH, Stephens O, SantraM, Williams DR,Dang L, BarlogieB, Shaughnessy JD Jr., KuehlWM, Staudt LM. Frequent engagementof the classical and alternative NF-kappaB tumor pathwaysby diverse genetic abnormalities in multiple myeloma. CancerCell 2007;12:115-130.
47. Weichert W, BoehmM, Gekeler V, BahraM, Langrehr J, NeuausP, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, JacobJ, Dietel M, Scheidereit C, Kristiansen G. High expression ofRelA/p65 is associated with activation of nuclear factor-kappaBdependentsignaling in pancreatic cancer andmarks a patient populationwith poor prognosis. Br J Cancer 2007;97:523-530.
48. Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, SwisherSG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biologyof esophageal adenocarcinoma after surgery is influenced bynuclear factor-kappaB expression. Cancer Epidemiol BiomarkersPrev 2007;16:1200-1205.
49. Rae C, Langa S, Tucker SJ, MacEwanDJ. Elevated NF-kappaB responsesand FLIP levels in leukemic but not normal lymphocytes:reduction by salicylate allows TNF-induced apoptosis. Proc NatlAcad Sci USA 2007;104:12790-12795.
50. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S,Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, KeeBL, Ferrando A, Miele L, Aifantis I. Targeting the NF- kappaBsignaling pathway in Notch1-induced T-cell leukemia. Nat Med2007;13:70-77.
51. Fabre C, Carvalho G, Tasdemir E, Braun T, Adès L, Grosjean J,Boehrer S, Métivier D, Souquère S, Pierron G, Fenaux P, KroemerG. NF-kappaB inhibition sensitizes to starvation-induced celldeath in high-risk myelodysplastic syndrome and acute myeloidleukemia. Oncogene 2007;26:4071-4083.
52. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosisof Epstein-Barrvirus(EBV)-transformed B cells and prolongssurvival of mice inoculated with EBV-transformed B cells. JVirol 2007;81:10029-10036.
53. Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. NF-kappaB2mutation targets TRAF1 to induce lymphomagenesis. Blood2007;110:743-751.
54. GeddesM, Balzi D, Buiatti E, Khlat M, Parkin D. Cancer in Italianmigrants. Cancer Causes Control 1991;2:133-140.
55. Iscovich J,Howe GR. Cancer incidence patterns (1972-91) amongmigrants from the Soviet Union to Israel. Cancer Causes Control1998;9:29-36.
56. Maskarinec G,Noh JJ.Theeffect ofmigration on cancer incidenceamong Japanese in Hawaii. Ethn Dis 2004;14:431-439.